Aspirin-based chemoprevention of colorectal cancer: The role for gut microbiota

Feiyu Diao1 | Shirong Cai2

1 Department of General Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, P. R. China
2 Division of Gastrointestinal Surgery Center, the First Affiliated Hospital of Sun Yat-sen University; Gastric Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510080, P. R. China

Correspondence
Dr. Shirong Cai, Division of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, P. R. China. Email: caishirong@yeah.net

1 | MAIN TEXT

Despite improvements in the surveillance, diagnosis, and multimodal therapies for colorectal cancer (CRC), its mortality is persistently high worldwide [1-3]. Continuing efforts for controlling CRC using similar strategies seems not sufficient given the persistent threats of CRC on human health. Prevention, in the form of chemoprevention, may provide another cost-effective way to enhance the outcomes of individuals at risk of developing CRC. In this regard, aspirin is emerging as a promising agent in the chemoprevention of CRC, especially for those at risk of cardiovascular diseases. However, the overall efficacy (∼30%) reported from multiple randomized controlled trials is still limited [4-6]. The reasons for the limited efficacies of aspirin are elusive. Genetic and epigenetic factors are thought to be critical in relation to drug responses [7, 8]. Cyclooxygenase-2 (COX-2) has been identified as one of the important factors affecting aspirin response. In one study by Chan et al. [9], the authors demonstrated that aspirin could reduce the risk of CRC in individuals that overexpressed COX-2 but not in those with a weak or absent expression of COX-2. The percentage of COX-2 overexpression in that study was 67%, much higher than the observed responsive rate in clinical trials [9]; suggesting that the status of COX-2 expression cannot fully explain the responsiveness to aspirin-based chemoprevention. Other factors associated with the chemopreventive efficacy of aspirin are still needed to be explored and elucidated.

Apart from host factors, a new research published in Gastroenterology by Zhao et al. delineates the instrumental role of the gut microbiota, one of the environmental factors, in modulating the chemopreventive effectiveness of aspirin [10]. The authors found that depletion of the gut microbiota by antibiotics cocktail enhanced the suppressive effect of aspirin on COX-2 and tumorigenesis in adenomatous polyposis coli gene-mutated (APCmin/+ ) mice and on mice supplemented with azoxymethane (AOM) and dextran sulfate sodium (DSS). This finding was then validated in germ-free mice which were treated with AOM/DSS, and aspirin was found to significantly inhibit COX-2 and tumorigenesis. The inhibitory effect was, however, abolished by the conventionalization of the germ-free mice. Further analysis revealed that microbiota depletion was associated with an elevated level of aspirin in the plasma. Co-incubation of microbes with aspirin demonstrated the aspirin-degrading effect of commensal bacteria. Through high-throughput functional screening of the commensal bacteria, the authors identified Lysinibacillus sphaericus (L. sphaericus) as a microbe that could degrade aspirin. Increase abundance of L. sphaericus in the gut not only reduced the plasma level of aspirin but also dampened the efficacy of aspirin on CRC chemoprevention. These findings indicated that some microbes, such as L. sphaericus, possessed a degrading effect on aspirin and could impair aspirin-base chemoprevention by reducing

Abbreviations: AOM, azoxymethane; APC, adenomatous polyposis coli; COX-2, cyclooxygenase-2; CRC, colorectal cancer; DSS, Dextran sulfate sodium; L. sphaericus, Lysinibacillus sphaericus
the aspirin level in the plasma. On the other hand, the authors profiled the composition of microbial communities in the feces of APCmin/+ mice with aspirin use and discovered that aspirin could enrich the abundance of *Bifidobacterium* and *Lactobacillus* in the fecal microbiota. By culturing the fecal microbiota, containing a higher abundance of *Bifidobacterium* and *Lactobacillus*, under aerobic and anaerobic conditions followed by transplantation of these microbiotas into germ-free mice supplemented with AOM and DSS, the authors found that tumorigenesis was markedly reduced in mice gavaged with anaerobic fecal culture, but not in those gavaged with aerobic fecal culture; indicating direct protection from parts of the aspirin-modulated microbiota in CRC development.

Thus, *L. sphaericus* in the gut microbiota degraded aspirin and reduced the intended effect of chemoprevention. Aspirin, in turn, could enrich *Bifidobacterium* and *Lactobacillus*, which provide some protective effect against CRC development. This is a timely and interesting study for uncovering the bidirectional interactions between the gut microbiota and aspirin for aspirin-based chemoprevention in CRC. On one hand, the gut microorganisms attenuated the preventive effect of aspirin by biotransformation of aspirin into its inactive metabolites, and on the other hand, aspirin enriched the abundance of some probiotics in the gut microbiota, which in turn provided some protections against CRC development (Figure 1).

Although the deactivation of aspirin by the gut microbiota, which can compromise the antithrombotic effect of aspirin, has already been previously reported [11], the study by Zhao et al. [10] is novel for identifying the bacterial species responsible for deactivating aspirin and potentially affecting aspirin CRC chemoprevention efficacy. The findings in this study have potential clinical relevance. For instance, if someone harbors a higher abundance of aspirin-degrading microbes, such as *L. sphaericus*, health care providers should be cautious when considering aspirin as the chemopreventive agent for CRC. Otherwise, *L. sphaericus*-mediated deactivation of aspirin could dampen the preventive effect of aspirin, while the gastrointestinal bleeding risk induced by aspirin could mountingly increase [12]. Although this study revealed that a higher abundance of *Bifidobacterium* and *Lactobacillus* lowered CRC risk, it may not mean to predict CRC risk with the abundance of probiotics or prevent CRC by increasing the colonization of probiotics. The enrichment of *Bifidobacterium* and *Lactobacillus* was merely one of the alterations induced by aspirin. Other bacteria modulated by aspirin may also have pros and cons impacts on CRC risk, which are still needed to be determined in further studies.

Since all the observations in the study by Zhao et al. [10] were conducted in mice, it is a long way to go towards clinical translation and human studies are still needed to validate these findings. Despite *L. sphaericus* was detected in the stool samples of some adenoma and healthy subjects, whether the bacteria could be colonized in the upper gastrointestinal tract, the main absorption site for aspirin, is yet to be determined. Although only *L. sphaericus* was
showed to possess an aspirin-degrading effect in this study, whether other microbes exert similar functions are still uncertain. Future researches on aspirin-based prevention for cardiovascular diseases or CRC should pay more attention on the aspect of the gut microbiota for discovering more microbial species with aspirin-degrading effect. Advanced sequencing techniques can equip us with more effective tools for deeper investigation of the gut microbiota; leading to the identification of specific microbial species, following long-term use of aspirin, in individuals developing CRC as compared to those not developing CRC. These species might be potential candidates in aspirin degradation. Additionally, further attempts should be taken to pinpoint the microbial enzymes deactivating aspirin. If we can find these functional enzymes, specific antibodies can be developed to block their catalytic activities.

In the future, capsules aspirin with these antibodies may protect aspirin from rapid degradation and thus, enhance the efficacy of aspirin in patients. These efforts would undoubtedly contribute to better guidance of personalized medicine using aspirin.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT FOR PUBLICATION
Not applicable.

AVAILABILITY OF DATA AND MATERIALS
Not applicable.

COMPETING INTERESTS
The authors declare that they have no competing interests.

FUNDING
This work was supported in part by the Project 5010 of Sun Yat-sen University (2018004) and a science and technology planning grant from Guangdong province to Shirong Cai.

AUTHORS’ CONTRIBUTIONS
Feiyu Diao and Shirong Cai wrote the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS
Not applicable.

REFERENCES
1. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020.
2. Wang ZQ, Zhang F, Deng T, et al. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Commun (Lond) 2019;39:26.
3. Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019;39:22.
4. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.
5. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38.
6. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
7. Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther 2019;197:122-152.
8. Rossi JF, Ceballos P, Lu ZY. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond) 2019;39:34.
9. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
10. Zhao R, Coker OO, Wu J, et al. Aspirin Reduces Colorectal Tumor Development in Mice and Gut Microbes Reduce its Bioavailability and Chemopreventive Effects. Gastroenterology 2020.
11. Kim IS, Yoo DH, Jung IH, et al. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem Pharmacol 2016;122:72-79.
12. Guo CG, Cheung KS, Zhang F, et al. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut 2020;69:445-452.

How to cite this article: Diao F, Cai S. Aspirin-based chemoprevention of colorectal cancer: the role for gut microbiota. Cancer Commun. 2020;40:633–635. https://doi.org/10.1002/cac2.12086